Brallobarbital

Brallobarbital is a barbiturate developed in the 1920s. It has sedative and hypnotic properties, and was used for the treatment of insomnia.

History

Brallobarbital was first synthesized in the 1920s by the pharmaceutical company Hoffmann-La Roche. It was marketed under the brand name Vesparax, often in combination with other drugs such as secobarbital and amobarbital.

Pharmacology

As a barbiturate, brallobarbital acts as a central nervous system depressant, producing effects ranging from mild sedation to total anesthesia. It works by enhancing the action of the neurotransmitter GABA in the brain, which results in a decrease in nerve cell activity.

Medical uses

Brallobarbital was primarily used as a treatment for insomnia. However, due to its potential for abuse and the development of tolerance, it has largely been replaced by other, safer medications.

Side effects

Common side effects of brallobarbital include drowsiness, dizziness, and impaired coordination. More serious side effects can include respiratory depression, addiction, and in rare cases, death.

Legal status

In many countries, brallobarbital is a controlled substance due to its potential for abuse and addiction.

See also

• Barbiturate
• Insomnia
• Hoffmann-La Roche

Brallobarbital

• 
  Brallobarbital chemical structure
• 
  Brallobarbital ball-and-stick model animation